News for Healthier Living

Experimental GLS1 Inhibitor Demonstrates Antitumor Activity in Advanced Treatment-Resistant Ovarian Cancer

Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase 1 trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of Texas MD Anderson Cancer Center.

November 18, 2026


November 19 2026

November 18 2026

November 17 2026

November 16 2026

November 15 2026

November 13 2026

November 12 2026

November 11 2026

November 10 2026

November 9 2026

November 8 2026

November 7 2026

November 6 2026

November 5 2026